

Symbiox Investment & Trading Co. Ltd.

221, Rabindra Sarani, 3rd Floor
Room No. 1, Kolkata - 700 007
Contact : 98302 74227
CIN : L65993WB1979PLC032012
Website : www.symbioxinvestment.com
E-mail : symbioxinvestment100@gmail.com

Date: 7th February, 2026

To,
Compliance Department
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th floor, Plot No C 62, G - Block,
Opp. Trident Hotel, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 098

To,
The Calcutta Stock Exchange Limited
7, Lyons Range,
Kolkata- 700 001

To,
The Bombay Stock Exchange Limited,
PJ Towers, Dalal Street
Mumbai- 400 001

Subject: Outcome of Board Meeting held on 7th February, 2026.

BSE Scrip Code: 539278 CSE Scrip Code: 029461 Symbol: SYMBIOX

Dear Sir,

We would like to inform you that the Meeting of Board of Directors of **M/s. Symbiox Investment & Trading Co Ltd** was held on **Saturday, 7th February, 2026** at its registered office address to inter-alia transact the following matters:

1. Pursuant to **Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**, approved the Unaudited Financial Results for the quarter ended on **31st December, 2025**.
2. Adopted Auditor's Limited Review Report given by Statutory Auditor of the Company for the quarter ended on **31st December, 2025**.
3. No other matters was transacted at the meeting.

Kindly note that the meeting of the Board of Directors **commenced at 02:30 P.M and concluded at 03:20 P.M.**

Please take the same on your record and acknowledge the receipt of the same.

Thanking You.

Yours Faithfully,

For Symbiox Investment & Trading Co Ltd


Khushboo Pitti
Company Secretary and Compliance Officer




SYMBIOX INVESTMENT & TRADING CO LTD
 221, RABINDRA SARANI, 3RD FLOOR, ROOM NO-1, KOLKATA -700007
 CIN - L65993WB1979PLC032012

Email - symbioxinvestment100@gmail.com; Website: www.symbioxinvestment.com

Statement of Unaudited Financial Result for the Quarter and nine months ended 31st Dec, 2025


(Rupees in Lakh except EPS)

	Particulars	Quarter ended			Nine months ended		Year ended
		31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31-03-25
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue From Operations	8.60	23.15	45.47	77.56	151.86	276.36
II	Other Income	0.04	0.00	0.04	0.23	0.04	0.43
III	Total Income (I+II)	8.64	23.15	45.51	77.79	151.90	276.79
IV	EXPENSES						
	Cost of materials consumed	-	-	-	0.00	0.00	0.00
	Purchases of Stock-in-Trade	0.00	24.19	79.14	33.67	157.10	332.12
	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	0.00	-21.06	-60.36	-7.26	-102.22	-120.68
	Employee benefits expense	5.18	6.14	2.86	15.39	10.56	15.34
	Finance costs	0.00	0.00	0.00	0.00	0.00	0.00
	Depreciation and amortization expense	0.07	0.07	0.08	0.22	0.22	0.29
	Other expenses	1.73	5.58	2.37	16.84	19.85	23.79
	Total expenses (IV)	6.98	14.92	24.09	58.86	85.51	250.86
V	Profit(loss) before exceptional items and tax (I- IV)	1.66	8.23	21.42	18.93	66.39	25.93
VI	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit(loss) before tax (V-VI)	1.66	8.23	21.42	18.93	66.39	25.93
VIII	Tax expense:						
	(1) Current tax	0.43	2.14	5.57	4.92	17.26	6.74
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	1.23	6.09	15.85	14.01	49.13	19.19
X	Profit(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit(loss) from Discontinued operations (after tax) (X-XI)	1.23	6.09	15.85	14.01	49.13	19.19
XIII	Profit(loss) for the period (IX+XII)	1.23	6.09	15.85	14.01	49.13	19.19
XIV	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	-	-	-	-	-	-
	Paid up equity share Capital (No. of Shares)	31287330	31287330	31287330	31287330	31287330	31287330
	Face Value	10.00	10.00	10.00	10.00	10.00	10.00
XVI	Earnings per equity share (for continuing operation):						
	(1) Basic	0.004	0.0195	0.051	0.045	0.157	0.061
	(2) Diluted	0.004	0.0195	0.051	0.045	0.157	0.061
XVII	Earnings per equity share (for discontinued operation):						
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000
XVIII	Earnings per equity share(for discontinued & continuing operations)						
	(1) Basic	0.000	0.000	0.000	0.000	0.000	0.000
	(2) Diluted	0.000	0.000	0.000	0.000	0.000	0.000




Note:	
1	The above Unaudited financial results were reviewed by Audit Committee and approved by the Board of Directors in their meeting held on 07th February, 2026.
2	The previous period figures have been regrouped wherever necessary.
3	The Statutory auditors of the Company have carried out a "Auditor's report" of the above results as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.
4	The Company has adopted Indian Accounting standards (Ind AS) with effect from 01 st April, 2017 and accordingly, the above results have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 prescribed under Section 133 of the Companies Act, 2013
5	The above results for the quarter & Nine months ended 31st Dec.,2025 along with Auditor Report has been approved by the Board of Directors of the Company.
6	There are no qualifications in the Audit Report issued by the Auditor

Place: Kolkata
Date: 07.02.2026



For and behalf of Board SYMBIOX INVESTMENT & TRADING CO.LTD

Samit Ray
Samit Ray
Managing Director
DIN No.08406285





SSRV & Associates

Chartered Accountants

Independent Auditors' Limited Review Report on quarterly unaudited standalone financial results of Symbiox Investment & Trading Co Ltd pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Review Report to
The Board of Directors,
Symbiox Investment & Trading Co. Limited
221, Rabindra Sarani, 3rd Floor
Room No. 1, Kolkata-700007.


1. We have reviewed the accompanying statement of unaudited financial results of **Symbiox Investment & Trading Co. Limited** ('the Company') for the quarter ended 31st December, 2025 (the "Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement

For SSRV & Associates
Chartered Accountants
Firm Reg. No.: 135901


Vishnu Kant Kabra
Partner
Membership No.: 403437
Place: Mumbai
Date: 07th February, 2026
UDIN: 26403437AABSXI2516

